Mrd Testing News Today

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

When my doctor told me, "I want to talk to you about something," I suddenly felt worried — thankfully it was good news.

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The